A study to evaluate virologic responses of patients with HCV genotype (GT) 1 infection receiving Ledipasvir/Sofosbuvir (LDV/SOF) with or without ribavirin (RBV) therapy

Trial Profile

A study to evaluate virologic responses of patients with HCV genotype (GT) 1 infection receiving Ledipasvir/Sofosbuvir (LDV/SOF) with or without ribavirin (RBV) therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2017 Results assessing virologic response (n=1021) published in the Drugs.
    • 17 Apr 2016 Status changed from active, no longer recruiting to completed, according to the results published.
    • 17 Apr 2016 Efficacy results (n=1091) presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top